Tazarotene — Discount Pricing

Other medications in Dermatology

• Tralokinumab
• Tretinoin
• Triamcinolone
• Triamcinolone Topical
• Urea Topical
• Acyclovir Topical
• Adapalene
• Anthralin

About Tazarotene

Tazarotene is a powerful topical retinoid used to treat conditions like acne, psoriasis, and sun-damaged skin. Known for its effectiveness, it can also be quite costly. With TheDrugClub, you can unlock significant savings on your tazarotene prescription, making this essential medication more accessible and affordable for your journey to healthier skin.

Tazarotene is a prescription-strength topical retinoid, a derivative of Vitamin A, widely recognized for its efficacy in treating various dermatological conditions. It's a key treatment for moderate to severe acne vulgaris, helping to clear existing blemishes and prevent new ones. Beyond acne, tazarotene is a cornerstone therapy for plaque psoriasis, a chronic autoimmune condition characterized by thick, scaly patches of skin. Additionally, it's approved for the treatment of facial fine wrinkles, mottled hyperpigmentation, and tactile roughness associated with photoaging (sun-damaged skin).

How Tazarotene Works

As a retinoid, tazarotene works by binding to specific retinoic acid receptors (RARs) found in skin cells. This interaction helps to normalize the growth and differentiation of skin cells, which are often disrupted in conditions like acne and psoriasis. For acne, it helps to unclog pores by promoting the shedding of dead skin cells and reducing inflammation. In psoriasis, tazarotene slows down the rapid overproduction of skin cells, reducing the characteristic scaling and redness. When used for photoaging, it encourages healthier cell turnover, leading to smoother skin texture and improved tone.

Typical Costs and TheDrugClub Savings

Without insurance or discount programs, tazarotene can be quite expensive. Brand-name versions like Tazorac or Arazlo, and even their generic equivalents, often cost hundreds of dollars for a single tube. This high price point can be a significant barrier for many individuals needing this effective treatment.

This is where TheDrugClub membership can make a substantial difference. Our members gain access to significantly reduced prices on medications like tazarotene. Through our negotiated discounts, you

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tazarotene is approved for (FDA label)

Trilitas™ gel, 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) Trilitas™ gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of Trilitas™ gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis Trilitas™ (tazarotene) gel, 0.1% is indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris Trilitas™ (tazarotene) gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity.

Source: Read the full FDA label on DailyMed. Label effective date: May 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tazarotene (FDA label)

Gel, 0.1%, in 30 g tube. Each gram of Trilitas™ gel, 0.1% contains 1 mg of tazarotene in a clear to yellow translucent, aqueous gel. Gel, 0.1% ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10. SPL document ID: 1f8c91db-194d-430b-a3b7-1d2e94c7b455. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tazarotene (FDA label)

The following serious adverse reactions are discussed in more detail in other sections of the labeling: Embryofetal toxicity [see Warnings and Precautions (5.1) ] Photosensitivity and Risk of Sunburn [see Warnings and Precautions (5.3) ] Plaque Psoriasis: Most common adverse reactions occurring in 10 to 30% of patients are pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, and skin pain. ( 6.1 ) Acne Vulgaris: Most common adverse reactions occurring in 10 to 30% of patients are desquamation, burning/stinging, dry skin, erythema and pruritus. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Perfero Pharma, Inc. at 1-973-629-0109 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10. SPL document ID: 1f8c91db-194d-430b-a3b7-1d2e94c7b455. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tazarotene (FDA label)

Trilitas™ gel is contraindicated in: Pregnancy. Retinoids may cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ]. Individuals who have known hypersensitivity to any of its components [see Warnings and Precautions (5.2) ]. Pregnancy ( 4 , 8.1 ) Hypersensitivity ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10. SPL document ID: 1f8c91db-194d-430b-a3b7-1d2e94c7b455. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tazarotene (FDA label)

Embryofetal Toxicity: Trilitas™ gel contains tazarotene, which is a teratogen. Trilitas™ gel is contraindicated in pregnancy. Females of child-bearing potential should have a negative pregnancy test within 2 weeks prior to initiating treatment and use an effective method of contraception during treatment. ( 5.1 ) Local Irritation: Excessive pruritus, burning, skin redness or peeling can occur. If these reactions occur, discontinue until the integrity of the skin has been restored, or consider reducing dosing frequency or in the case of psoriasis, consider switching to the lower concentration. Trilitas™ gel should not be used on eczematous skin, as it may cause severe irritation. ( 5.2 ) Photosensitivity and Risk for Sunburn: Avoid exposure to sunlight, sunlamps, and weather extremes. Wear sunscreen daily.

Source: FDA prescribing information (DailyMed). Set ID: 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10. SPL document ID: 1f8c91db-194d-430b-a3b7-1d2e94c7b455. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tazarotene (FDA label)

No formal drug-drug interaction studies were conducted with Trilitas™ gel. In a trial of 27 healthy female subjects between the ages of 20–55 years receiving a combination oral contraceptive tablet containing 1 mg norethindrone and 35 mcg ethinyl estradiol, concomitant use of tazarotene administered as 1.1 mg orally (mean ± SD C max and AUC 0-24 of tazarotenic acid were 28.9 ± 9.4 ng/mL and 120.6 ± 28.5 ng∙hr/mL, respectively) did not affect the pharmacokinetics of norethindrone and ethinyl estradiol over a complete cycle. The impact of tazarotene on the pharmacokinetics of progestin only oral contraceptives (i.e., minipills) has not been evaluated.

Source: FDA prescribing information (DailyMed). Set ID: 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10. SPL document ID: 1f8c91db-194d-430b-a3b7-1d2e94c7b455. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.